Literature DB >> 3947506

Relationship between plasma concentrations of clonidine and mean arterial pressure during an accidental clonidine overdose.

L E Domino, S E Domino, M S Stockstill.   

Abstract

The time course of toxicity in a 28 year old man following a 100 mg accidental overdose of clonidine hydrochloride is compared with the decline of plasma clonidine over 5 days. The concentration data were analyzed by nonlinear least squares regression, and fitted to a model which dissociated the blood pressure effects into pressor and depressor components. According to this analysis, there appeared to be two phases of toxicity over time--a hypertensive, and a hypotensive phase. The hypotensive and the hypertensive phases may result primarily through differential stimulation of central alpha 2-, alpha 1-, and vascular post-synaptic alpha 2-adrenoceptors as plasma concentrations fall.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3947506      PMCID: PMC1400798          DOI: 10.1111/j.1365-2125.1986.tb02824.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

Review 1.  Central alpha-adrenergic systems as targets for hypotensive drugs.

Authors: 
Journal:  Rev Physiol Biochem Pharmacol       Date:  1978       Impact factor: 5.545

2.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

3.  Multiple receptor responses: a new concept to describe the relationship between pharmacological effects and pharmacokinetics of a drug: studies on clonidine in the rat and cat.

Authors:  L K Paalzow; P O Edlund
Journal:  J Pharmacokinet Biopharm       Date:  1979-10

4.  Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension.

Authors:  L M Wing; J L Reid; D S Davies; E A Neill; P Tippett; C T Dollery
Journal:  Eur J Clin Pharmacol       Date:  1977-12-28       Impact factor: 2.953

5.  Apparent resistance to hypotensive effect of clonidine.

Authors:  L M Wing; J L Reid; D S Davies; H J Dargie; C T Dollery
Journal:  Br Med J       Date:  1977-01-15

6.  A newly developed precise and sensitive radioimmunoassay for clonidine.

Authors:  D Arndts; H Stähle; C J Struck
Journal:  Arzneimittelforschung       Date:  1979

7.  Relationship between the cardiovascular effects and steady-state kinetics of clonidine in hypertension. Demonstration of a therapeutic window in man.

Authors:  M Frisk-Holmberg; L Paalzow; L Wibell
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 8.  Clonidine overdose: a review.

Authors:  C S Conner; A S Watanabe
Journal:  Am J Hosp Pharm       Date:  1979-07

9.  Clonidine withdrawal in hypertension. Changes in blood-pressure and plasma and urinary noradrenaline.

Authors:  J L Reid; L M Wing; H J Dargie; C A Hamilton; D S Davies; C T Dollery
Journal:  Lancet       Date:  1977-06-04       Impact factor: 79.321

  9 in total
  5 in total

1.  Dermal exposure to a compounded pain cream resulting in severely elevated clonidine concentration.

Authors:  Adam C Pomerleau; Casey E Gooden; Corinne R Fantz; Brent W Morgan
Journal:  J Med Toxicol       Date:  2014-03

Review 2.  Is clonidine an effective smoking cessation therapy?

Authors:  S G Gourlay; N L Benowitz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of clonidine.

Authors:  D T Lowenthal; K M Matzek; T R MacGregor
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

Review 4.  Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.

Authors:  Henry A Spiller; Hannah L Hays; Alfred Aleguas
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

Review 5.  Centrally acting antihypertensive agents: an update.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-05       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.